MindMed to treat cluster headaches using LSD, announces phase 2 trials
Category: #health  By Pankaj Singh  Date: 2020-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

MindMed to treat cluster headaches using LSD, announces phase 2 trials
  • The LSD based drug will be used to treat chronic cluster headaches occurring on one side of the head or over the eye.
  • These trials will be conducted in collaboration with Liechti Lab, University of Basil. Phase 1 trials for the drug are already underway.

It has recently been announced that Mind Medicine Inc. will be collaborating with Liechti Lab at University Hospital Basel, on Phase 2 clinical trials of LSD for treating cluster headaches. The Phase 1 clinical trials for the same have already begun with several patients already recruited into the program. This will be a randomized, double-blind, cross over study and phase 2 trials will investigate the effects of LSD in 30 patients compared with placebo.

MindMed is a neuro-pharmaceutical company that works on psychedelic inspired medicines and has previously formed an R&D collaboration with Liechti Lab – a global clinical laboratory for LSD at the University Hospital, Basel to analyze therapeutic uses of next generation of psychedelics. Dr. Mathias Liechti is the current principal investigator for this trial.

Cluster headaches, or in other words “suicide headaches” are one of the most painful conditions ailing mankind. This pain can last for numerous weeks or months and usually occurs above an eye or on one side of the head. Up until now, there is only non-clinical evidence that suggests LSD can be used to abort or decrease the frequency of these types of attacks. There is currently a need for new treatment in this domain as the current medication available often mismanages attack periods.

On the phase 2 approval of these trials, JR Rahn, MindMed Co-CEO and Co-Founder said that he was encouraged to bring the treatment of cluster headaches through LSD out of the shadows. He also said that they were testing the efficacy of this drug on clinical research standards with Liechti Lab.

This collaboration will test the commercial feasibility of this drug, and on favorable results, the company will look for an FDA approval. MindMed hopes that treatments for this illness might qualify under the Orphan Drug Designation and that the drug is eligible for development incentives through the FDA.

MindMed and Liechti Lab hope to develop a more targeted approach for the treatment of cluster headaches through these trials. MindMed will be having access to all the data generated for cluster headaches.

Source Credits: https://www.prnewswire.com/news-releases/phase-2-clinical-trial-of-lsd-for-suicide-headaches-begins-treating-patients-301071869.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...